{
    "Project Title": "A Phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life",
    "Sponsor": "Amgen, Inc.",
    "Study Number": "CC-10004-PSOR-020",
    "Protocol Version and Date": "Amendment 3 FINAL: 01 May 2020",
    "Study Title": "A Phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life",
    "Phase": "Phase 4",
    "Therapeutic Area": "Plaque Psoriasis",
    "Number of Patients": 255,
    "Number of Sites": "Not Available",
    "Indication": "Psoriasis vulgaris",
    "Duration of Treatment": "52 weeks",
    "Schedule of Assessments": "Table 3: Table of Events (Section 5)",
    "questionnaires": [
        {
            "longName": "Dermatology Life Quality Index",
            "shortName": "DLQI",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 1   (Screening  )",
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Static Physicians Global Assessment of Visible Locations",
            "shortName": "sPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 1   (Screening  )",
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Scalp Physician Global Assessment",
            "shortName": "ScPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 1   (Screening  )",
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Nail Psoriasis Severity Index",
            "shortName": "NAPSI",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc",
                "Visit Number: 1   (Screening  )"
            ]
        },
        {
            "longName": "Modified Static Physicians Global Assessment of Genitalia",
            "shortName": "Modified sPGA-G",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 1   (Screening  )",
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Palmoplantar Psoriasis Physicians Global Assessment",
            "shortName": "PPPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 1   (Screening  )",
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Itch Numeric Rating Scale",
            "shortName": "NRS",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Skin Discomfort/Pain Visual Analog Scale",
            "shortName": "VAS",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Body Surface Area",
            "shortName": "BSA",
            "type": "None",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Psoriasis Area Severity Index",
            "shortName": "PASI",
            "type": "ClinRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 3",
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 6   (Apremilast Extension Phaseb  )",
                "Visit Number: 7",
                "Visit Number: 9/ETc",
                "Visit Number: 1   (Screening  )"
            ]
        },
        {
            "longName": "Patient Benefit Index",
            "shortName": "PBI",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 32, 52",
            "questionnaireTiming": [
                "Visit Number: 4",
                "Visit Number: 5",
                "Visit Number: 7",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "European Quality of Life 5-Dimension Questionnaire",
            "shortName": "EQ-5D",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 5",
                "Visit Number: 9/ETc"
            ]
        },
        {
            "longName": "Work Productivity and Activity Impairment Questionnaire: Psoriasis",
            "shortName": "WPAI: PSO",
            "type": "PRO",
            "questionnaireSchedule": "Weeks 0, 16, 52",
            "questionnaireTiming": [
                "Visit Number: Baseline 2   (Placebo-Controlled Phasea  )",
                "Visit Number: 5",
                "Visit Number: 9/ETc"
            ]
        }
    ]
}